Showing posts with label Dementia. Show all posts
Showing posts with label Dementia. Show all posts

January 27, 2015

Tuesday, January 27, 2015
A new study reveals that higher doses or prolonged use of medications with anticholinergic effects significantly increases the risk for developing dementia.  Although, this is not the first study to discover such a link, it is the first to suggest that the risk of dementia as a result of taking such medications may not be reversible.
“An anticholinergic agent is a substance that blocks the neurotransmitter acetylcholine in the central and the peripheral nervous system. Anticholinergics inhibit parasympathetic nerve impulses by selectively blocking the binding of the neurotransmitter acetylcholine to its receptor in nerve cells. The nerve fibers of the parasympathetic system are responsible for the involuntary movement of smooth muscles present in the gastrointestinal tract, urinary tract, lungs, etc.”
Anticholinergic agents are used to treat a variety of conditions such as gastrointestinal disorders, respiratory disorders, insomnia, dizziness etc.  Some of these commonly used medications include Diphenhydramine (Benadryl, Advil PM etc.), Bupropion (Zyban, Wellbutrin), Dextromethorphan (cough suppressant) and the list goes on.  In addition, some of these medications can be acquired without a prescription and can have very strong anticholinergic effects.

Moreover, many older patients, already at higher risk of developing dementia, are frequently using these types of medications.  Doctors should be taking a proactive approach and monitoring the use of these drugs, including non-prescription use.
“For instance, the most commonly used medications in the study were tricyclic antidepressants like doxepin (Sinequan), first-generation antihistamines like chlorpheniramine (Chlor-Trimeton), and antimuscarinics for bladder control like oxybutynin (Ditropan). The study estimated that people taking at least 10 mg/day of doxepin, 4 mg/day of chlorpheniramine, or 5 mg/day of oxybutynin for more than three years would be at greater risk for developing dementia.”
Consequently, the study suggests that medical professionals should seek substitutes such as citalopram (Celexa) or fluoxitene (Prozac) for depression or loratadine (Claritin) for allergies or behavioral changes for urinary incontinence.  However, if substitutes are not available, the suggestion is to prescribe the lowest dose possible, monitor its effectiveness closely and cease use if there is no real benefit to the patient.

This study differs from other research as it used more rigorous methods, longer follow-up periods and better assessment of medication use by using pharmacy records of both prescription and non-prescription use.  It is also the first of its kind to link anticholinergic medication dosages to dementia risk.  Results were obtained by tracking nearly 3,500 Group Health seniors participating in the long-running Adult Changes in Thought study (a longitudinal population-based prospective cohort study of brain aging and incident dementia in the Seattle metropolitan area), some of which have also agreed to have their brains autopsied after they die.  Stay tuned.

Quick Facts:

Dementia is a general term for a decline in mental ability severe enough to interfere with daily life.

Alzheimer's is the most common type of dementia.

While symptoms of dementia can vary greatly, at least two of the following core mental functions must be significantly impaired to be considered dementia:

• Memory
• Communication and language
• Ability to focus and pay attention
• Reasoning and judgment
• Visual perception

Many dementias are progressive, meaning symptoms start out slowly and gradually get worse.
Dementia is caused by damage to brain cells, which interferes with the ability of brain cells to communicate with each other.

There is no one test to determine if someone has dementia. Doctors diagnose Alzheimer's and other types of dementia based on a careful medical history, a physical examination, laboratory tests, and the characteristic changes in thinking, day-to-day function and behavior associated with each type.

Some risk factors for dementia, such as age and genetics, cannot be changed, however some of the most active areas of research in risk reduction and prevention include cardiovascular factors, physical fitness, and diet.

The total number of new cases of dementia each year worldwide is nearly 7.7 million, implying one new case every four seconds. The number of people with dementia is expected to nearly double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050.

The costs are estimated at US$ 604 billion per year at present and are set to increase even more quickly than the prevalence.

Caring for dementia patients is overwhelming for caregivers. The stresses include physical, emotional and economic pressures. Care givers require support from the health, social, financial and legal systems.

People with dementia are frequently denied the basic rights and freedoms available to others. For example, physical and chemical restraints are used extensively in aged-care facilities and acute-care settings.

Improving the awareness and understanding of dementia across all levels of society is needed to decrease discrimination and to improve the quality of life for people with dementia and their caregivers.

More research is needed to develop new and more effective treatments and to better understand the causes of dementia. Research that identifies the modifiable risk factors of dementia is still scarce.

Higher dementia risk linked to more use of common drugs
Anticholinergic
alz.org
World Health Organization

© www.mentalhealthblog.com

January 19, 2013

Saturday, January 19, 2013

Research shows that the use of choline supplements during pregnancy may prevent schizophrenia.  Specifically, lower rates of physiological schizophrenic risk factors in infants 33 days old has been noted when the dietary supplement is given during the second and third trimesters of pregnancy and early infancy.

Robert Freedman, MD, professor and chairman of the Department of Psychiatry, University of Colorado School of Medicine and one of the study's authors states: "Basic research indicates that choline supplementation during pregnancy facilitates cognitive functioning in offspring. Our finding that it ameliorates some of the pathophysiology associated with risk for schizophrenia now requires longer-term follow-up to assess whether it decreases risk for the later development of illness as well."

Choline is a water-soluble essential nutrient, typically grouped within the B-complex vitamins. It can be found naturally in foods such as liver, muscle meats, fish, nuts and eggs.  According to the American Institute of Medicine, pregnant women require between 450 and 3500 milligrams of choline each day and 550 to 3500 milligrams while lactating.  Infants aged 0-6 months need a minimum daily dose of 125 milligrams of choline and 150 milligrams from 7-12 months of age.

“Choline is also being studied for potential benefits in liver disease, including chronic hepatitis and cirrhosis, depression, memory loss, Alzheimer's disease and dementia, and certain types of seizures.”

To test their theory, researchers observed infant responses to a clicking sound.  Typically, the brain responds fully to an initial click, however the response to a second click immediately following the first is inhibited.  This trait is often absent among schizophrenia patients and relates to poor sensory filtering and familial transmission of schizophrenia risk.  Researchers observed this effect among infants to represent the illness as schizophrenia does not normally appear until adolescence.

“Half the healthy pregnant women in this study took 3,600 milligrams of phosphatidylcholine each morning and 2,700 milligrams each evening; the other half took placebo. After delivery, their infants received 100 milligrams of phosphatidylcholine per day or placebo. Eighty-six percent of infants exposed to pre- and postnatal choline supplementation, compared to 43% of unexposed infants, inhibited the response to repeated sounds, as measured with EEG sensors placed on the baby's head during sleep.”

These results could not only assist in early detection of schizophrenia, but may even help in preventing the illness or developing more effective treatments.

Some examples of choline found in different food sources:

Type of Food
mg of choline
5 ounces (142 g) raw beef liver
473
Large hardboiled egg
113
Half a pound (227 g) cod fish
190
Half a pound of chicken
150
Quart of milk, 1% fat
173
A gram soy lecithin
30
100 grams of Soybeans dry
116
A pound (454 grams) of cauliflower
177
A pound of spinach
113
A cup of wheat germ
202
Two cups (0.47 liters) firm tofu
142
Two cups of cooked kidney beans
108
A cup of uncooked quinoa
119
A cup of uncooked amaranth
135
A grapefruit
19
Three cups (710 cc) cooked brown rice
54
A cup (146 g) of peanuts
77
A cup (143 g) of almonds
74

Choline Supplementation DuringPregnancy Presents a New Approach to Schizophrenia Prevention
Choline

November 26, 2012

Monday, November 26, 2012
Researchers at the University of Texas Medical Branch at Galveston revealed that an FDA-approved medication called rosiglitazone that is used to treat insulin resistance in diabetics also enhances learning and memory. This discovery could improve cognitive performance for those with Alzheimer’s disease.

By studying genetically engineered mice designed to serve as models for Alzheimer's, “the scientists believe that the drug produced the response by reducing the negative influence of Alzheimer's on the behavior of a key brain-signaling molecule.”

The molecule in question is called extracellular signal-regulated kinase (ERK). In the brains of Alzheimer's patients as well as the mice in the study, this molecule becomes hyperactive, which leads to improper synaptic transmission between neurons thereby interfering with learning and memory.

“Rosiglitazone brings ERK back into line by activating what's known as the peroxisome proliferator-activated receptor gamma (PPARγ) pathway, which interacts with genes that respond to both PPARγ and ERK.”

Basically, the medication helps to restore signals between neurons so that cognitive functions become more normal. This research opens a gateway allowing researchers to test more FDA-approved drugs to try and normalize insulin resistance in Alzheimer's patients while potentially improving their memory at the same time. It could also lead to a greater understanding of the biology behind the cognitive issues in Alzheimer's disease.

Alzheimer's disease (AD) is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death.

Symptoms:
  • Memory loss that disrupts daily life.
  • Challenges in planning or solving problems.
  • Difficulty completing familiar tasks at home, at work or at leisure.
  • Confusion with time or place.
  • Trouble understanding visual images and spatial relationships.
  • New problems with words in speaking or writing.
  • Misplacing things and losing the ability to retrace steps.
  • Decreased or poor judgment.
  • Withdrawal from work or social activities.
  • Changes in mood and personality.
Prevalence:
  • An estimated 5.4 million Americans of all ages have Alzheimer’s disease in 2012. This figure includes 5.2 million people age 65 and older and 200,000 individuals under age 65 who have younger-onset Alzheimer’s.
  • One in eight people age 65 and older (13 percent) has Alzheimer’s disease.
  • Nearly half of people age 85 and older (45 percent) have Alzheimer’s disease.
  • Of those with Alzheimer’s disease…
    • an estimated 4 percent are under age 65
    • 6 percent are 65 to 74
    • 44 percent are 75 to 84
    • 46 percent are 85 or older
  • Every 68 seconds, someone in America develops Alzheimer’s.
  • By mid-century, someone in America will develop the disease every 33 seconds.
Diabetes Drug Improves Memory, Study Suggests
Alzheimer's disease
Facts and Figures facts and figures

© www.mentalhealthblog.com

October 5, 2012

Friday, October 05, 2012
Researchers from the Department of Dental Medicine and the Aging Research Center (ARC) at Karolinska Institutet and from Karlstad University in Sweden suggest that the loss of chewing ability may be linked to cognitive decline and a higher risk of dementia.

Dementia is a serious loss of global cognitive ability in a previously unimpaired person, beyond what might be expected from normal aging. It is not considered a single disease, but rather a set of signs and symptoms, in which affected areas of cognition may be memory, attention, language, and problem solving.

The study randomly selected a nationwide sample of 577 participants aged 77 or older to investigate tooth loss, chewing ability and cognitive function. Results showed that individuals that experienced more difficulty chewing hard foods were more at risk of developing cognitive impairments, even when controlling other variables such as sex, age, education and mental health. In addition, chewing with dentures or real teeth had no impact on their results.

It could be that “few or no teeth makes chewing difficult, which leads to a reduction in the blood flow to the brain. However, to date there has been no direct investigation into the significance of chewing ability in a national representative sample of elderly people.”

Unfortunately, this study does not specify whether all participants consumed similarly nutritious meals. Those with a reduced ability to chew certain foods may have been malnourished, which could have played a major role in their cognitive decline.

Nevertheless, the preliminary results of such research certainly provide further support for the fact that oral health impacts overall health. Good oral health brings significant benefits to self-esteem, dignity, social integration and general nutrition.

According the World Health Organization, the proportion of people aged 60 years and older is growing faster than any other age group, as a result of both longer life expectancy and declining fertility rates. Therefore, as our society ages, this type of research becomes more and more relevant…

  • As of 2010, more than 35.6 million people worldwide are living with dementia, or more than the total population of Canada.

  • The global prevalence of dementia stands to double every 20 years, to 65.7 million in 2030, and 115.4 million in 2050.

  • Total health-care costs for people with dementia amount to more than 1 per cent of the global gross domestic product (GDP), or US$604 billion in 2010.
Chewing Ability Linked to Reduced Dementia Risk
Dementia
Ageing
Facts about dementia

© www.mentalhealthblog.com

September 19, 2012

Wednesday, September 19, 2012
New research conducted by the Rush Alzheimer's Disease Center at Rush University Medical Center suggests that emotionally neglected children are at risk of stroke as adults. 
"Studies have shown that children who were neglected emotionally in childhood are at an increased risk of a slew of psychiatric disorders. However, our study is one of few that looked at an association between emotional neglect and stroke," said study author Robert S. Wilson, PhD, a neuropsychologist at Rush.
Researchers’ selected 1,040 participants aged 55+ without dementia from the Memory and Aging Project were surveyed on physical and emotional abuse before the age of 18. Participants were questioned on such areas as how much love they felt from their parents or caregivers as children, whether they felt afraid or intimidated by their caregivers, the method of physical punishment suffered and other questions relating to divorce and family finances.

The participants were followed over a period of 3.5 years. In that time, 257 participants had died. Of the deceased participants, only 192 had brain autopsies, which revealed that 89 of them had experienced strokes. Furthermore, forty of the participants were said to have had strokes based on medical history or an examination.

Furthermore, participants that expressed moderately high levels of emotional neglect in childhood were nearly 3 times more likely to experience a stroke than those reporting moderately low levels of emotional childhood neglect, even when other factors such as diabetes, physical activity, smoking, anxiety and heart problems were controlled.

"The results add to a growing body of evidence suggesting that early life factors such as traumatic childhood experiences influence the development of physical illness and common chronic conditions of old age" says Dr. David A. Bennett, director of the Rush Alzheimer's Disease Center and co-author of the study
Of course results may not be completely reliable since this study relies on a self-report of recalled events many years later, which may be even further clouded given the nature of the potentially traumatic memories.

Emotional Neglect in Children Linked to Increased Stroke Risk Later in Life

© www.mentalhealthblog.com

March 27, 2011

Sunday, March 27, 2011

According to researchers at Temple University's School of Medicine, the popular asthma drug, Zileuton, has shown potential in treating Alzheimer’s disease. This medication works by reducing the amount of amyloid beta that develops and accumulates in the aging brain. Amyloid beta is a peptide that has been known to be involved in the development of Alzheimer's disease.
“In previous studies, the Temple researchers discovered that 5-lipoxygenase, an enzyme long known to exist in the brain, controls the activation state of gamma secretase, another enzyme that is necessary and responsible for the final production of amyloid beta. When produced in excess, amyloid beta causes neuronal death and forms plaques in the brain. The amount of these amyloid plaques in the brain is used as a measurement of the severity of Alzheimer's.”
“Zileuton (trade name ZYFLO) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation.“

Domenico Praticò and fellow researchers tested the effects of this drug on genetically engineered mice with Alzheimer's disease. Results showed that amyloid production and build-up in the brain was reduced by 50% by treating the mice with Zileuton.

Researchers are already aware of substances that can block gamma secretase’s production of amyloid, however completely eliminating a vital function may result in other health problems, such as developing cancer. “Unlike classical gamma secretase inhibitors, Zileuton only modulates the protein expression levels, which keeps some of its vital functions in tact while blocking many of its bad effects, which in this case is the development of the amyloid plaques.”

Fortunately, if clinic trials effectively demonstrate Zileuton’s ability to treat Alzheimer’s disease, the medication could be readily available to patients as it is already FDA-approved and on the market.

In addition, further research may uncover treatments for other untreatable diseases resulting from amyloid plaques accumulating in the brain, such as cerebral amyloid angiopathy, a neurological condition that occurs when amyloid proteins build up on the walls of the arteries in the brain, which increases the risk of hemorrhagic stroke and dementia.

Asthma Drug Could Help Control or Treat Alzheimer's Disease
Zileuton
Cerebral amyloid angiopathy

© www.mentalhealthblog.com

March 14, 2009

Saturday, March 14, 2009
Imagine a home that turned its lights on or off when needed, turned taps off when left on, warned you that appliances were not shut off or remained hot, or one that encouraged you to go back to bed at night if you were caught wandering the house. Believe it or not, the University of Bath has developed this futuristic ‘smart home’, which uses cutting edge sensor, electronics and IT capabilities to revolutionize the lives of dementia sufferers.

Two nursing homes in the UK are currently using this new technology and have been for a year with great success. These trial homes will provide the necessary insight required for the conversion of regular homes to smart homes for those living on their own with dementia.

Professor Roger Orpwood, the lead scientist behind the systems' development, assures the public that this new technology seeks to solve unique problems affecting people in a way that empowers and enables them to maintain control of their own lives rather than taking away individual control.

An easy to use ‘plug in and use’ type of device will certainly prevent excessive feelings of helplessness and improve the quality of life for those living with dementia by allowing them to remain more independent. In addition, monitoring normally performed by family members will be taken over by this new system. Consequently, the extra burden on family members will be replaced with feelings of security. As well, the costs of homecare will be vastly reduced.

“The key will be to tailor them to individual requirements and ensure that they act as much like a live-in carer as possible. For example, voice-prompts can utilise the voices of relatives or friends to deliver reassuring messages, as well as to influence behaviour. The systems are also designed to be monitored remotely via computer by healthcare professionals” says Professor Orpwood.

These high tech renovations sound like a dream come true for people living with dementia, but how much could this dream home cost? Expense is an important factor as people tend to be surviving on limited income at the age where dementia typically sets in. Additionally, let’s hope this system can be transferred effortlessly to a new home since many elderly people, although independent; prefer the comforts of a condo to a large home. Nevertheless, the benefits seem far greater than any downfall or limitation of this new invention.

New 'Smart' Homes For Dementia Sufferers

© www.mentalhealthblog.com

Popular Posts

Dentalget.com is dental equipment supplier, we provide high quality dental instruments, dental handpiece at a discount price. Free shipping worldwide.

Categories

9/11 AADD Abortion Academic Success Acetylcholine ADD Adderall Addiction ADHD Adult Attention Deficit Disorder Adultery Advertising Aggression Aging Agreeableness AIDS Air Pressure Alcohol Alcohol Abuse Alcohol Dependence Alcoholism alpha-CaM kinase II Altitude Alzheimer's Amphetamine Amygdala Amyloid Amyloid Deposition Anesthesia Anger Anterior Cingulate Cortex Anterograde Amnesia Anti-Depressants Anti-Psychotic Anticholinergic Anticonvulsant Antiepileptic Antioxidants Anxiety Anxious-Avoidant Anxious-Preoccupied Apolipoprotein E Army Aromatherapy Asperger Syndrome Assessment Associative Learning Asthma Attachment Theory Attention Attention Deficit Disorder Attention Deficit Hyperactivity Disorder Autism Autism Spectrum Disorder Autonomic Nervous System Average Sleep Requirements B-type Natriuretic Peptide Babies Balance Behavioral Problems Behaviour Behavioural Impairment Behavioural Therapy Benadryl Bipolar Disorder Blood Clot Blood Pressure Blue Light Blue Light Goggles Body Mass Index Bone Marrow Brain Brain Development Brain Imaging Brain Injury Brain Stem Brain Surgery Breast Cancer Buddhism bullying Bupropion Business C-reactive Protein Calories CAMH Canada Canadian Charter of Rights and Freedoms Cancer Carbohydrates Cardiovascular Disease Care Facilities Caregiver cars Cdk5 Cell Phone Central Nervous System Centre for Addiction and Mental Health Cerebellum Cerebral Amyloid Angiopathy Cerebral Cortex Cerebrospinal Fluid Cerebrovascular Accident Cerebrovascular Insult Chat Rooms Chewing Childhood Disabilities Childhood Disintegrative Disorder Childhood Emotional Neglect Children Chitin Chitosan Cholesterol Choline Chromosome Chronic Pain Syndrome Chronic Stress Circadian Rhythm Cirrhosis Citalopram Classical Conditioning Climate Change Clot-Busting Drug Co-morbidity Cocaine Cognition Cognitive Development Cognitive Impairment Colloquially Brain Attack Coma Communication Device Communication Technology Concentration Concerta Concussion Conflict Confusion Conscientiousness Control Group Coordination Correlation Cortisol Counselling Couples CPAP Crack CRASH-2 CRASH-3 Creativity Criminal Code Cyberbullying Cyberpsychology Cyklokapron Daytrana Death Death Toll Decision-Making Declarative Memory Deep Brain Stimulation Delusion Dementia Dentures Depression Destrostat Deviant Behaviour Dexedrine Dextromethorphan Diabetes Diet Dietary Supplements Diphenhydramine Disability discrimination Dismissive-Avoidant Disorganized Attachment Disorganized Speech Disorientation Dizziness Docosahexaenoic Acid (DHA) Double-Blind Dream Drinking Drowsiness Drug Abuse Drug Dependence Drug Use Drugs DSM DSM-5 Dual Diagnosis Early Onset Alzheimer's Economic Crisis Ecstasy Effexor Ego Eicosapentaenoic Acid (EPA) Elderly Electrical Stimulation Electroconvulsive Therapy Electrodes Email Embitterment Embolic Emotion Emotional Neglect Emotional Problems Emotional Well-Being Employee Enrivonment Enzyme Epilepsy Estrogen Ethics Evolution Experimental Group Extracellular Signal-Regulated Kinase (ERK) Extroversion Facebook Facebook Fan Page Facebook Friends Family Family Therapy Fast Food Father Father Absenteeism Fatherhood FDA Fear Fearful-Avoidant FeelingBetterNow Fetus Fibrin Fish Oil fluoxetine fMRI Focalin Focus Food Fraud Friday Gamma Secretase Genetic Disorders Genetics Ginkgo Biloba Glucose Glutamate Receptor God Gout Guest Blogger Hair Pulling Haiti Hallucination Hallucinogenic Halo Effect Harm-Reduction Headache Healthy Eating Hearing Heart Attack Heart Disease Hematopoietic Stem Cells Hepatitis Hepatitis C Herbal Supplements Hereditary Angioedema Heredity Heroin High Blood Pressure Hippocampus Hockey Homelessness Hormone Housing Hox Genes Hoxb8 Cells Human Rights Hydromorphone Hyper-social Networker Hyperactivity Hypothalamus Illness Impulse Control Impulsivity Inattentiveness Infant Infidelity Inflammation Insecure Attachment Insomnia Instant Messaging Insulin Intellectual Development Intellectual Disability Internet Intracranial Bleeding Introversion Introvert Ischemic Stroke KASPAR Ketamine Ketogenic Kleptomania Laptop Latent Inhibition Learning Learning Disability Leukotrienes Limbic System Lithium Liver Locked-In Syndrome Long Term Memory Long-Term Potentiation Longevity Lupus Lysteda Maestro Rechargeable System Major Depression Mania MAOI Marriage MDMA Medication Meditation Melatonin Memory Memory Loss Memory Task Men Mental Health Mental Health Forum Mental Heath Mental Illness Metadate Metyrapone Mice Microglia Mild Cognitive Impairment (MCI) Mild Traumatic Brain Injury Military Mind-Body Mindless Eating Mitochondria MOHLTC Mood Disorder Morphine Mortality Rates MRI MS-275 Multiple Sclerosis Muscle Weakness music therapy Narcissism Natasha Richardson National Sleep Foundation Natural Disaster Nature/Nurture Nausea Necrosis Neglect Nerve Neuro-imaging Neurobiology Neurodegeneration Neurodegenrative Diseases Neurodevelopment Disorders Neurogenesis Neurological Disease Neuromarketing Neuron Neuropathy Neuroticism Neurotransmitter News Nintendo Wii Non-REM Sleep Nose Nurse Ratched Nutrition Obesity Obessive Compulsive Spectrum Disorder (OCD) Offspring Olfactory Gland OM3 Emotional Balance Omega 3 Ontario Ontario Review Board Ontario Works Opioid Oral Health Organic Ottawa Over-activity Over-Medication Ovulation Oxidative Cell Oxygen Oxytocin p35 Pacemaker Pain Pain Killer Pain Management Pancreatic Polypeptide Pancreatitis Paralysis Paranoia Paraskevidekatriaphobia Parenthood Parents Parkinson's Paroxetine Paxil PDD-NOS perception Perfume Peripheral Nervous System Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Pathway personality traits Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) PET Scan Pharmacology Phobias Physical Health Physiological Plasmin Plasminogen Plasticity Platelet-Activating Factor Politics Post-Concussion Assessment and Cognitive Test (ImPACT) Potassium Ion Channel Poverty Pregnancy Pressure Procedural Memory Promiscuity Prozac PsychBoard.com Psychiatric Ward Psychological Psychological Inventories Psychologist Psychology Psychology Forum Psychology of Eating Psychosis PTED PTSD Public Health Pyromania Quadriplegic Rehab Relationships Reliability Religion REM Research Retigabine Retrograde Amnesia Rett Syndrome Risperdal Ritalin road rage Robot Robotics Rodent Research Rosiglitazone Samsung Satiety Scales Schizophrenia School Screening Secure Attachment Sedatives Seizure Self-Affirmation Intervention Self-Confidence Self-Esteem Self-Integrity Self-Worth Semantic Memory Senior Seroquel Serotonin Serzone Sex Sex Therapy Sexual Orientation Sexual Satisfaction Shock Therapy Sideline Concussion Assessment Test (SCAT2) Sleep Sleep Apnea Sleep Disorders Sleep Quality Sleep Stages Smartphone Smoking Snacking Sniffing Technology Social Assistance Social Deficits Social Isolation Social Media Social Network Social Rejection Social Skills Social Worker Socialization Societal Change Soft Palate Soldier Somatic Nervous System Spatial Memory Special K Speech Spinal Cord Spinal Cord Injury Spinal Tap Sports Injury SSRI Statin Stem Cell Stimulant Strattera Stress Stress Hormone Stroke Substance Abuse Sugar Suicide Superstition Support Survey Suspicious Tablet Talk Therapy Tamoxifen Tanorexia Tax Payer Technology Television Telomere Temperature Testosterone Texting Therapy Thorazine Threshold Thrombosis Thrombotic Tinnitus Tissue Plasminogen Activator Topographical Disorientation Tranexamic Acid Trauma Treatment Tremors Trial Tribunal Trichotillomania Type-2 Diabetes Vagus Nerve Validity Ventromedial Prefrontal Cortex Video Games Virtual Reality Vision Visual Attention Vitamin B Vitamins Vitiligo Voice Vyvanse Walnuts Weight Loss Welfare Wellbutrin Wernicke–Korsakoff syndrome Wet Brain White Blood Cells Women Work World Health Organization Zileuton Zyban Zyprexa µ-opiate receptors (MOR)